EUVIMEDEUVIMED entdecken
Crossref

Improvement and characterization of oral absorption behavior of clofazimine by SNEDDS: Quantitative evaluation of extensive lymphatic transport

Keita Yamanouchi, Tomoki Ishimaru, Takuya Kakuno, Yuki Takemoto, Sho Kawatsu, Keiji Kondo, Masato Maruyama, Kazutaka Higaki

European Journal of Pharmaceutics and Biopharmaceutics · 2023-06 · 187 · 141-155

DOI: 10.1016/j.ejpb.2023.04.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023-06. Verfasst von Keita Yamanouchi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan. Hauptthemen laut MEDLINE: Clofazimine, Nanoparticles. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clofazimine, an anti-leprosy drug, has been anticipated for a candidate to treat tuberculosis, cryptosporidiosis, and coronavirus infection, but its low oral bioavailability is considered a reason for its limited activity. In the current study, we have tried to improve the oral bioavailability of clofazimine by several SNEDDS formulations and characterized the absorption behavior from various aspects. Among four SNEDDS formulations prepared, SNEDDS A, prepared with castor oil as an oil component, provided the highest bioavailability (around 61%) and SNEDDS D, prepared with Capryol 90, gave the second highest bioavailability. SNEDDS A formed the finest nanoparticles, which were maintained under gastric and intestinal luminal conditions. The comparison in oral bioavailability between the SNEDDS formulation and its corresponding preformed nanoemulsion suggested that SNEDDS A would efficiently form nanoemulsion in the gastrointestinal tract after oral administration. AUC of mesenteric lymph node concentration was the highest for SNEDDS A, which would be one of the reasons for SNEDDS A to reveal the highest oral bioavailability. A cycloheximide-treated oral absorption study and single-pass perfusion study by utilizing a vascular-luminal perfused small intestine-liver preparation clearly indicated that over 90% of clofazimine absorbed to systemic circulation should be derived from lymphatic transport for both SNEDDS A and D. Furthermore, the fraction of dose absorbed was around 65% for SNEDDS D, but SNEDDS A achieved around 94%, indicating the excellent performance of SNEDDS A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClofazimineNanoparticlesDrug Delivery SystemsSolubilityPharmaceutical PreparationsAdministration, OralBiological AvailabilityEmulsionsParticle Size

Stichwörter der Autor:innen

Castor oilClofazimineLymphatic transportOral absorptionSNEDDSVascular-luminal perfusion

Substanzen

ClofaziminePharmaceutical PreparationsEmulsions

Autor:innen und Institutionen

  • Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan.
  • Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan; Department of Drug Metabolism and Pharmacokinetics, Nonclinical Research Center…
  • Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan; Pharmaceutical Research Laboratories, Pharmaceutical Department, Nipro Co. 3023…
  • Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan; Formulation Design, Pharmaceutical Research and Technology Laboratories, Pharma…
  • Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan; Preformulation Research Laboratory, CMC Headquarters, Otsuka Pharmaceutical Co.…
  • Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan. Electronic address: higaki@okayama-u.ac.jp.

Zitieren

APA

Yamanouchi, K., Ishimaru, T., Kakuno, T., Takemoto, Y., Kawatsu, S., Kondo, K., Maruyama, M., & Higaki, K. (2023). Improvement and characterization of oral absorption behavior of clofazimine by SNEDDS: Quantitative evaluation of extensive lymphatic transport. European Journal of Pharmaceutics and Biopharmaceutics, 187, 141-155. https://doi.org/10.1016/j.ejpb.2023.04.009

Vancouver

Yamanouchi K, Ishimaru T, Kakuno T, Takemoto Y, Kawatsu S, Kondo K, et al. Improvement and characterization of oral absorption behavior of clofazimine by SNEDDS: Quantitative evaluation of extensive lymphatic transport. European Journal of Pharmaceutics and Biopharmaceutics. 2023;187:141-155. doi:10.1016/j.ejpb.2023.04.009

BibTeX
@article{Yamanouchi2023,
  author = {Yamanouchi, Keita and Ishimaru, Tomoki and Kakuno, Takuya and Takemoto, Yuki and Kawatsu, Sho and Kondo, Keiji and Maruyama, Masato and Higaki, Kazutaka},
  title = {Improvement and characterization of oral absorption behavior of clofazimine by SNEDDS: Quantitative evaluation of extensive lymphatic transport},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2023},
  volume = {187},
  pages = {141--155},
  doi = {10.1016/j.ejpb.2023.04.009}
}
Kostenlos starten →